IRIS
TOSCA, ELENA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.409
AS - Asia 993
EU - Europa 862
SA - Sud America 256
AF - Africa 17
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.542
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.373
CN - Cina 375
SG - Singapore 265
IT - Italia 234
BR - Brasile 210
IE - Irlanda 184
RU - Federazione Russa 160
HK - Hong Kong 121
VN - Vietnam 121
DE - Germania 84
FI - Finlandia 39
GB - Regno Unito 34
FR - Francia 24
SE - Svezia 20
AR - Argentina 19
IN - India 19
JP - Giappone 18
MX - Messico 16
NL - Olanda 15
PL - Polonia 15
CA - Canada 12
ES - Italia 12
AT - Austria 11
IR - Iran 10
BD - Bangladesh 7
CO - Colombia 7
CZ - Repubblica Ceca 7
BE - Belgio 6
EC - Ecuador 6
IQ - Iraq 6
MY - Malesia 6
ZA - Sudafrica 6
DO - Repubblica Dominicana 5
ID - Indonesia 5
AE - Emirati Arabi Uniti 4
TR - Turchia 4
CL - Cile 3
LK - Sri Lanka 3
PE - Perù 3
PK - Pakistan 3
TN - Tunisia 3
TW - Taiwan 3
UA - Ucraina 3
UY - Uruguay 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
CH - Svizzera 2
HU - Ungheria 2
JO - Giordania 2
KE - Kenya 2
KR - Corea 2
KZ - Kazakistan 2
LT - Lituania 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
SA - Arabia Saudita 2
VE - Venezuela 2
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BY - Bielorussia 1
DM - Dominica 1
DZ - Algeria 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MN - Mongolia 1
MU - Mauritius 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.542
Salva come PNG Salva come JPEG
Città #
Dallas 297
Dublin 184
Chandler 148
Ashburn 136
Singapore 125
Hong Kong 120
Beijing 108
Pavia 71
Boardman 69
Los Angeles 67
Ho Chi Minh City 55
New York 42
Shanghai 41
Moscow 37
Munich 36
Nanjing 32
Redondo Beach 32
São Paulo 27
Lawrence 26
Medford 26
Princeton 26
Milan 25
Buffalo 21
Hanoi 20
Wilmington 20
Helsinki 18
Turku 18
Dearborn 17
Jacksonville 17
Shenyang 17
Hebei 15
Florence 14
Nanchang 14
Warsaw 14
Tokyo 13
Brooklyn 12
Guangzhou 10
Rome 10
Stockholm 10
Tianjin 10
Changsha 9
Santa Clara 9
Ann Arbor 8
Denver 8
Frankfurt am Main 8
Jiaxing 8
Mexico City 8
Montreal 8
Nuremberg 8
Rio de Janeiro 8
Chicago 7
Eindhoven 7
Poplar 7
Atlanta 6
Brescia 6
Düsseldorf 6
Houston 6
Johannesburg 6
London 6
Mira 6
Orem 6
San Francisco 6
Washington 6
Boston 5
Brussels 5
Chennai 5
Fortaleza 5
Girifalco 5
Heemskerk 5
Hyderabad 5
Kunming 5
Paris 5
Pittsburgh 5
Porto Alegre 5
Seattle 5
Tehran 5
Brasília 4
Cagliari 4
Castano Primo 4
Da Nang 4
Fairfield 4
Falkenstein 4
Genoa 4
Hangzhou 4
Hefei 4
Moncalieri 4
Norwalk 4
Phoenix 4
Vienna 4
Ankara 3
Baghdad 3
Biên Hòa 3
Brno 3
Bắc Ninh 3
Can Tho 3
Colombo 3
Curitiba 3
Dhaka 3
Graz 3
Hải Dương 3
Totale 2.313
Salva come PNG Salva come JPEG
Nome #
Quantitative evaluation of RC-106 antitumor activity in GBM spheroids through tumor growth inhibition modeling based on cell counts data 156
Dynamic energy budget based models of tumor-in-host growth inhibition and cachexia onset in preclinical settings. 105
Evaluation of software tools for Bayesian estimation on population models:an update based on current software versions 101
Methods and tools for multiscale modelling in Systems Pharmacology: a review 99
Leveraging Two-Stage delta Global Sensitivity Analysis method to inform parameter estimation in PBPK models 95
Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics? 93
A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens 91
Translating Preclinical Insights into Clinical Outcomes: A Predictive Framework for Overall response rate and time to progression in Solid Tumors 90
Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach 89
Cancer Cachexia: A Dynamic Energy Budget ({DEB})-Based Model for Tumor-Related Anorexia and Sarcopenia 89
Dealing with stochasticity in precision dosing decision-making processes by fully exploiting PK-PD modelling in Reinforcement Learning algorithms. A practical case-study on Vancomycin continuous infusion in ICU patients 81
Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment 81
A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats 79
In vitro– in vivo correlation (Ivivc) population modeling for the in silico bioequivalence of a long‐acting release formulation of progesterone 79
A genetic algorithm for covariate selection 76
Model-based analysis of patient-derived organoids for evaluating anticancer drugs 75
A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies 75
An integrated pipeline for evaluating antitumor efficacy of RC-106 on glioblastoma spheroids 74
Evaluation of a tumor growth inhibition (TGI) model integrating dynamic energy budget (DEB) theory 74
Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like Molecules 72
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity 72
Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients 69
Facing the limits of the genetic algorithms for covariate selection 69
In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone 69
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib 68
A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance 67
Dynamic Energy Budget (DEB) based models of tumor-in-host growth inhibition and cachexia onset 66
Development of a genetic algorithm for covariate analysis in population pharmacokinetic models 66
Modeling resistance development to Bevacizumab in xenograft experiments by coupling hypoxia-mediated mechanism and a Dynamic Energy Budget (DEB) based tumor-in-host model 64
A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics 60
Precision dosing by integrating Reinforcement Learning and PK-PD models: application to givinostat treatment of Polycythemia Vera 58
Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach 57
Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator 56
Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat 55
How Modelling and Simulations combined with Artificial Intelligence can improve Precision Dosing 55
A Two-Stages Global Sensitivity Analysis by using the delta sensitivity index in presence of correlated inputs: Application on a Tumor Growth Inhibition model based on the Dynamic Energy Budget theory 54
PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population 54
Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach 53
mvLognCorrEst: an R package for sampling from multivariate lognormal distributions and estimating correlations from uncomplete correlation matrix 52
A Two-Stages Global Sensitivity Analysis in presence of correlated inputs: Application on a Tumor-in-host-growth Inhibition model based on the Dynamic Energy Budget theory 51
PopPK-PD modelling of Carboplatin-induced myelosuppression to support therapeutic drug monitoring and dose individualization in cancer patients using Electronic Health Record Data 50
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment 49
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients 49
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach 46
Staggered Herringbone Microfluid Device for the Manufacturing of Chitosan/TPP Nanoparticles: Systematic Optimization and Preliminary Biological Evaluation 46
Precision Dosing in Presence of Multiobjective Therapies by Integrating Reinforcement Learning and PK-PD Models: Application to Givinostat Treatment of Polycythemia Vera 45
Go beyond the limits of genetic algorithm in daily covariate selection practice 44
Model-informed reinforcement learning for enabling precision dosing via adaptive dosing 43
Translational modeling of tumor response to treatment: bridging preclinical to clinical studies 43
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients 42
Predicting ADMET properties from molecule SMILE: a bottom-up approach using attention-based Graph Neural Networks 42
A clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera 39
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma 38
Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach 34
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach 31
Impact of sampling procedure on individual pharmacokinetic parameter estimation methods 22
Totale 3.652
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 2 3 9 4 5 1 1
2021/2022151 2 2 10 0 4 4 7 27 10 5 18 62
2022/2023440 48 41 6 27 25 36 2 30 199 1 9 16
2023/2024303 27 62 15 14 25 54 18 20 6 16 8 38
2024/2025901 18 97 35 35 43 11 43 44 220 49 103 203
2025/20261.602 191 252 344 410 340 65 0 0 0 0 0 0
Totale 3.652